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Abstract
Multi-arm multi-stage trials can improve the efficiency of the drug development process when multiple
new treatments are available for testing. A group-sequential approach can be used in order to design
multi-arm multi-stage trials, using an extension to Dunnett’s multiple-testing procedure. The actual sample
size used in such a trial is a random variable that has high variability. This can cause problems when
applying for funding as the cost will also be generally highly variable. This motivates a type of design that
provides the efficiency advantages of a group-sequential multi-arm multi-stage design, but has a fixed
sample size. One such design is the two-stage drop-the-losers design, in which a number of
experimental treatments, and a control treatment, are assessed at a prescheduled interim analysis. The
best-performing experimental treatment and the control treatment then continue to a second stage. In
this paper, we discuss extending this design to have more than two stages, which is shown to considerably
reduce the sample size required. We also compare the resulting sample size requirements to the sample
size distribution of analogous group-sequential multi-arm multi-stage designs. The sample size required for
a multi-stage drop-the-losers design is usually higher than, but close to, the median sample size of a group-
sequential multi-arm multi-stage trial. In many practical scenarios, the disadvantage of a slight loss in
average efficiency would be overcome by the huge advantage of a fixed sample size. We assess the
impact of delay between recruitment and assessment as well as unknown variance on the drop-the-
losers designs.
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1 Introduction
Testing multiple experimental treatments against a control treatment in the same trial provides
several advantages over doing so in separate trials. The main advantage is a reduced sample size
due to a shared control group being used instead of a separate control group for each treatment.
Other advantages include that direct comparisons can be made between experimental treatments and
that it is administratively easier to apply for and run one multi-arm clinical trial compared to several
traditional trials.1 Multi-arm multi-stage (MAMS) clinical trials include interim analyses so that
experimental treatments can be dropped if they are ineffective; also, if desired, the trial can be
designed so that it allows early stopping for efficacy if an effective experimental treatment is
found. Two current MAMS trials that are ongoing are the MRC STAMPEDE trial,1 and the
TelmisArtan and InsuLin Resistance in HIV (TAILoR) trial (the design of which is discussed in
Magirr, Jaki and Whitehead2).
Magirr et al.2 extend Dunnett’s multiple-testing procedure3 to multiple stages, which we refer to
as the group-sequential MAMS design. In this design, futility and efficacy boundaries are
prespecified for each stage of the trial. At each interim analysis, statistics comparing each
experimental treatment to the control treatment are calculated and compared to these
boundaries. If a statistic is below the futility boundary, then the respective experimental arm is
dropped from the trial. If a statistic is above the efficacy threshold, the trial is stopped with that
experimental treatment recommended. Boundaries would generally be required to control the
frequentist operating characteristics of the trial. Since there are infinitely many boundaries that
do so, a specific boundary can be chosen to minimise the expected number of recruited patients
at some treatment effect,4 or by using some boundary function such as those of Pocock,5 O’Brien
and Fleming,6 or Whitehead and Stratton.7
The group-sequential MAMS design is efficient in terms of the expected sample size recruited, but
has the practical problem that the sample size used is a random variable. This makes planning a trial
more difficult than when the sample size is known in advance. An academic investigator applying for
funding to conduct a MAMS trial will find that traditional funding mechanisms lack the required
flexibility to account for a random sample size.8 Generally, they would have to apply for the
maximum amount that could potentially be used, with the consequence that such trials appear
highly expensive to fund. There are also several other logistical issues to consider, such as
employing trial staff to work on a trial with a random duration.
An alternative type of MAMS trial is one in which a fixed number of treatments is dropped at
each interim analysis. Stallard and Friede9 propose a group-sequential design where a set number
of treatments is dropped at each interim analysis, and the trial stops if the best-performing test
statistic is above a predefined efficacy threshold or below a predefined futility threshold. The
stopping boundaries are set assuming the maximum test statistic is the sum of the maximum
independent increments in the test statistic at each stage, which is generally not true and leads
to conservative operating characteristics. A special case of Stallard and Friede’s design is the well-
studied two-stage drop-the-losers design,10,11 in which one interim analysis is conducted, and only
the top-performing experimental treatment and a control treatment proceed to the second stage.
In Thall et al.,10 the chosen experimental treatment must be sufficiently effective to continue to the
second stage. More flexible two-stage designs have been proposed by several authors, including
Bretz et al.12 and Schmidli et al.13 These designs used closed testing procedures and/or
combination tests to control the probability of making a type-I error whilst allowing many
modifications to be made at the interim. In the case of multiple experimental arms, there is
more scope for improved efficiency by including additional interim analyses, at least for
group-sequential MAMS designs.2,4
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In this paper, we extend the two-stage drop-the-losers design to more than two stages and derive
formulae for the frequentist operating characteristics of the design. The resulting design has the
advantage of a fixed sample size by maintaining a prespecified schedule of when treatments are
dropped. That is, at each interim analysis, a fixed number of treatments are dropped. Note that this
could be thought of as subdividing the first stage of a two-stage drop-the-losers trial to allow
multiple stages of selection. We show that when there are several treatments, allowing an
additional stage of selection noticeably decreases the sample size required for a given power,
compared to the two-stage design. We also compare the multi-stage drop-the-losers design to the
Dunnett-type MAMS design.
2 Notation
We assume that the trial is to have J stages, that is, J  1 interim analyses and a final analysis, and
starts with K experimental treatments and a control treatment. Let k 2 0, 1, . . . ,Kf g index the
treatment (k¼ 0 represents the control treatment). Cumulative up to the end of the jth stage of
the trial, a total of nj patients have been recruited to each remaining treatment. The number of
treatments to be dropped at each stage (i.e. values of nj) are prespecified, and in particular do not
depend on the results of the trial. The ith patient allocated to treatment k has a treatment outcome,
Xki, distributed as N k, 
2
 
. The value of 2 is assumed to be known.
For k 2 1, . . . ,Kf g, define k ¼ k  0. The null hypotheses to be tested are HðkÞ0 : k  0. The
global null hypothesis, HG, is defined as HG : 1 ¼ 2 ¼    ¼ K ¼ 0. The known variance test
statistic for treatment k at stage j is
Z
kð Þ
j ¼
Pnj
i¼1Xki
nj

Pnj
i¼1X0i
nj
  ffiffiffiffiffiffiffi
nj
22
r
ð1Þ
which has marginal distribution N k
ffiffiffiffiffi
nj
22
q
, 1
 
.
The covariance between different test statistics can be shown to be
Cov Z
ðkÞ
j ,Z
ðmÞ
l
 
¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
minðnj, nl Þ
maxðnj, nl Þ
s
if k ¼ m;
ffiffiffi
1
2
r ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
minðnj, nl Þ
maxðnj, nl Þ
s
if k 6¼ m
8>>>>><
>>>>>:
ð2Þ
At each stage, a fixed and predetermined number of experimental treatments are dropped. Let n(j)
denote the number of experimental treatments continuing into stage j. For J stages, the design is
denoted as a K : nð2Þ : . . . : nðJ1Þ : nðJÞ design, where K4 nð2Þ4    4 nðJ1Þ4 nðJÞ. Thus, at least one
experimental treatment is dropped at each analysis. Although n(J) can in principle be more than one,
we henceforth only consider designs with n(J)¼ 1, similar to a two-stage drop-the-losers design. The
experimental treatments to be dropped are determined by ranking the Z
ðkÞ
j statistics of the remaining
experimental treatments in order of magnitude, and removing the smallest (least promising) as
prespecified by the design. The control treatment always remains in the trial. At the final
analysis, one experimental treatment remains, and if its final test statistic is above a threshold, c,
that treatment is recommended, and the respective null hypothesis rejected.
It is desirable that the design is chosen in order to control the family-wise type-I error rate
(FWER). The FWER is the probability of rejecting at least one true null hypothesis, and strong
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control of the FWER at level  means that the FWER is   for any configuration of true and false
null hypotheses (i.e. for any values of k, k ¼ 1, . . . ,K). In Section 3, we demonstrate how to control
the FWER at 1¼ 2¼. . .¼ K¼ 0, and show in Section 4 that this strongly controls the FWER. As
well as the FWER, it is also desirable to control the probability of selecting a genuinely good
treatment, were it to exist. To formalise the latter quantity, we use the least favourable
configuration (LFC) of Dunnett3 and consider the probability of recommending treatment 1
when 1¼ (1) and 2¼ 3¼. . .¼ K¼ (0), where (1) is a prespecified clinically relevant effect, and
(0) is some threshold below which a treatment is considered uninteresting. The configuration is
called least favourable as it minimises the probability of recommending a treatment with effect
greater than or equal to (1) amongst all configurations where at least one treatment has a
treatment effect of (1) or higher and no treatment effects lie in the interval ((0), (1)).10
3 Analytic operating characteristics
In this section, we provide analytical formulae for the probability of a particular treatment being
recommended under a general vector of treatment effects. We also provide formulae for the
probability of rejecting any null hypothesis when HG is true, and the probability to select the best
treatment under the LFC. Although the formulae extend naturally to more than three stages, the
expressions grow in length with the number of stages. For simplicity of exposition, we concentrate
on the three-stage case, where K experimental treatments are included in the first stage, L<K in the
second stage, and 1 in the third stage. This is denoted as the K : L : 1 design.
3.1 Probability of a specific treatment being recommended
For subsequent development, it is useful to define a ranking of the experimental treatments in terms
of how successful they are in the trial. We introduce random variables  ¼  1, . . . , Kð Þ, where  k is
the ranking of treatment k. Each of the  ks takes a unique integer value between 1 and K with the
following properties:
(1) the treatment that reaches the final analysis has rank 1;
(2) the treatment that is dropped at the first analysis with the lowest test statistic is given rank, K;
(3) if treatment k1 reaches a later stage than treatment k2, then  k15 k2 , that is, treatment k1 has a
higher ranking;
(4) if treatments k1 and k2 are dropped at the same stage, and k1 has a higher test statistic at that
stage, then  k15 k2 .
For instance, for a three-stage 4:2:1 design where treatment 3 reaches the final stage, treatment
2 is dropped at the second analysis, treatments 1 and 4 are dropped at the first analysis,
and treatment 1 has the lowest test statistic at the first analysis, the realised value of  is
(4, 2, 1, 3).
For J¼ 3, the probability of recommending treatment k, that is, rejecting HðkÞ0 , given the mean
vector  ¼ 1, 2, . . . , Kð Þ can be written in terms of  as
P Reject H
ðkÞ
0 j
 
¼ P  k ¼ 1,ZðkÞ3 4 cj
 
ð3Þ
that is, the kth null hypothesis is rejected only if the kth experimental treatment reaches the final
stage and its test statistic there is above the critical value c. Without loss of generality, consider the
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probability of recommending treatment 1. Let  be the set of all possible realisation of  . Then the
right-hand side of equation (4) becomesX
 2: 1¼1
P Z
ð1Þ
3 4 c, j
 
ð4Þ
We next show how each of the summands in equation (4) can be written as the tail probability of a
multivariate normal distribution. The distribution of Z ¼ Zð1Þ1 ,Zð1Þ2 ,Zð1Þ3 , . . . ,ZðKÞ1 ,ZðKÞ2 ,ZðKÞ3
 
is
multivariate normal and we denote its mean by m() and covariance by , where these are
defined by equations (1) and (2), respectively. Consider first the event that  1 ¼ 1,
 2 ¼ 2, . . . , K ¼ K, and Zð1Þ3 4 c. This event occurs if
Z
ðkÞ
1 4Z
ðLþ1Þ
1 for all k ¼ 1, . . . ,L
and
Z
ðLþ1Þ
1 4Z
ðLþ2Þ
1 4    4ZðKÞ1
in order that treatments Lþ 1, . . . ,K are eliminated with the desired ordering after the first stage,
and
Z
ð1Þ
2 4Z
ð2Þ
2 4    4ZðLÞ2
so treatments 2, . . . ,L are eliminated with the desired ordering after the second stage, and finally
Z
ð1Þ
3 4 c
The specified event can be expressed in terms of conditions on differences between entries of Z plus
the final condition Z
ð1Þ
3 4 c. For example, the condition Z
ðkÞ
1 4Z
ðLþ1Þ
1 for all k ¼ 1, . . . ,L is
equivalent to the L inequalities
Z
ð1Þ
1  ZðLþ1Þ1 4 0, . . . ,ZðLÞ1  ZðLþ1Þ1 4 0
In all, there are Kþ L 2 inequalities involving pairs of elements of Z and one involving a single
element of Z. This set of inequalities can be written in terms of a transformed variable AZ where A is
a ðKþ L 1Þ  JKmatrix and each of the first Kþ L 2 rows of A picks out the difference between
two elements of Z, while the last row picks out Z
ð1Þ
3 . As an example, in the 4 : 2 : 1 design, the event
 1 ¼ 1, 2 ¼ 2, . . . K ¼ K,Zð1Þ3 4 c
 
has
A ¼
0 0 0 0 0 0 1 0 0 1 0 0
1 0 0 0 0 0 1 0 0 0 0 0
0 0 0 1 0 0 1 0 0 0 0 0
0 1 0 0 1 0 0 0 0 0 0 0
0 0 1 0 0 0 0 0 0 0 0 0
0
BBBBBB@
1
CCCCCCA
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and the requirements for the event to occur are
AZð Þi4 0 for i ¼ 1, . . . , 4 and AZð Þ54 c
Now, AZ is an affine transformation of a multivariate normal random variable, and so is normal with
mean Am() and covariance matrix AAT. Thus, the event  1 ¼ 1, 2 ¼ 2, . . .ð  K ¼ K,Zð1Þ3 4 cÞ can
be expressed as a multivariate normal tail probability, which can be evaluated efficiently using the
method of Genz and Bretz.14
Other terms in equation (4), in which the values of  2, . . . , K are different permutations of the
indices 2, . . . ,K, can be dealt with in a similar way. Computationally, one can simply permute the
entries of the treatment effect vector  in a suitable way so that the formulae for the case
 1 ¼ 1,  2 ¼ 2, . . . , K ¼ K can be applied and the matrix A and associated covariance matrix
AAT remain unchanged.
The above approach extends directly to designs with more than three stages. For a
K : nð2Þ : nð3Þ : . . . : nðJ1Þ : 1 design, at the end of stage j 2 1, . . . , J 1f g, nð j Þ  1 conditions are
imposed to ensure that the correct treatments are retained and the dropped treatments have the
specified ordering. With one final condition to ensure that the Z statistic for the top-ranked
treatment exceeds the critical value c at the final analysis, the total number of conditions is
1þ K 1ð Þ þ
XJ1
j¼2
nð j Þ  1 
so the matrix A has this number of rows and JK columns.
3.2 Probability of recommending any treatment under the global null
hypothesis
When the global null hypothesis HG is true, each element of m() is 0. By symmetry, the probability
of observing each ordering  and a final Z statistic greater than c is the same. Thus, the probability
of recommending any treatment under the global null hypothesis is
K ! P  1 ¼ 1, 2 ¼ 2, . . . , K ¼ K,Zð1ÞJ 4 cj ¼ 0
 
ð5Þ
and this needs the calculation of a single multivariate normal random variable, as described in
Section 3.1.
3.3 Probability of recommending a specific treatment under the LFC
We assume the trial is to be powered to recommend treatment 1 at the LFC, where 1  0 ¼ ð1Þ
and k  0 ¼ ð0Þ for k ¼ 2, . . . ,K. Thus, the probability of recommending treatment 1 is
K 1ð Þ! P  1 ¼ 1, 2 ¼ 2, . . . , K ¼ K,Zð1ÞJ 4 cj1 ¼ ð1Þ, 2 ¼ ð0Þ, . . . , K ¼ ð0Þ
 
ð6Þ
and this can be calculated as ðK 1Þ! times the tail probability of a single multivariate normal
random variable.
R code provided online (https://sites.google.com/site/jmswason) allows the user to find the values
of n and c so that a design has required FWER and power.
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4 Strong control of FWER
We can control the probability of recommending an ineffective treatment when the global null
hypothesis HG is true by specifying the critical value c so that the probability (5) is equal to . In
the case of a group-sequential MAMS trial, controlling the error rate under HG has been shown to
control the FWER in the strong sense.2 In this section, we prove that controlling the FWER at the
global null hypothesis strongly controls the FWER for the multi-stage drop-the-losers design also.
We denote by mj, the fixed number of observations collected in stage j on each surviving treatment
and on the control arm. At the end of stage j, the cumulative sample size on each remaining
treatment and the control arm is nj ¼ m1 þ . . .þmj. Without loss of generality, we assume just
one treatment is eliminated in each stage: the reason there is no loss of generality here is that if
two or more treatments are to be eliminated, we can suppose that data-gathering stages with sample
size mj¼ 0 take place between each elimination.
Initially the set of indices of all treatments is
I0 ¼ f1, . . . ,Kg
and after a treatment has been eliminated at the end of stage j, we denote the set of indices of the
K  j remaining treatments by Ij.
Recall for k ¼ 1, . . . ,K, we denote the observations on treatment k in stages 1 to j by Xki,
i ¼ 1, . . . , nj, and denote the corresponding observations on the control arm by X0i, i ¼ 1, . . . , nj.
For each k 2 Ij1, the difference between the sum of responses on treatment k and the control at the
end of stage j is
Sj,k ¼
Xnj
i¼1
Xki  X0ið Þ
We define the terms Sj,k for k 2 Ij1 since these are the statistics observed after gathering new data in
stage j. The values Sj,k, k 2 Ij1, are used to select the treatment to be eliminated at the end of
stage j, and the values Sj,k, k 2 Ij, are then carried forward. The set IK1 contains just one treatment
index and after data are gathered on this treatment and control in stage K, this Sj,K is used to decide
whether or not the one treatment in IK1 is superior to the control.
We first consider the general case where treatments 1 to K have treatment effects 1, . . . , K
relative to the control treatment. For notational convenience, we set
S0,k ¼ 0, k ¼ 1, . . . ,K
With normally distributed responses of common variance 2, we can describe the data gathering in
stage j  1 by writing
Sj,k ¼ Sj1,k þmjk þ j,k
ffiffiffiffiffiffiffiffiffiffi
mj2
q
þ j
ffiffiffiffiffiffiffiffiffiffi
mj2
q
ð7Þ
where all the j,k and j are independent N(0, 1) random variables. Here, j,k is associated with the
responses on treatment k in stage j; j is associated with responses on the common control arm in
stage j and these terms introduce correlation into the sums Sj,k, k 2 Ij1.
After the data-gathering part of stage j, the treatment kj with the lowest Sj,k for k 2 Ij1 is
eliminated, leaving
Ij ¼ Ij1n kj
n o
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After the penultimate stage K  1, one treatment, klast say, remains in IK1 and this treatment and
the control are observed in the final stage, K. After stage K, the statistic including the final-stage data
is SK,klast . If
SK, klast4 c
H0 : klast  0 is rejected in favour of klast4 0.
The trial is designed to have type-I error probability  when 1 ¼ . . . ¼ K ¼ 0. We wish to show
this also implies strong control of the FWER for testing the family of hypotheses H
ðkÞ
0 : k  0,
k ¼ 1, . . . ,K.
Consider two trials that have the same design but differ with respect to values of the treatment
effects. In Trial 1, 1 ¼ . . . ¼ K ¼ 0 and we use the notation described above. We define a parallel
set of notation for Trial 2. We denote the treatment effects in Trial 2 by l, l ¼ 1, . . . ,K, and suppose
some of the l may be positive, and others negative or equal to zero. Let Lj denote the set of indices
of treatments still in the trial after stage j of Trial 2 and
Nj ¼ l : l 2 Lj and l  0
	 

so a type-I error will only occur if one of the hypotheses H0 : l  0 for l 2 Nj is eventually rejected.
For j ¼ 1, . . . ,K 1, let Tj,l, l 2 Lj1 be the analogues of Trial 1’s Sj,k, k 2 Ij1. For j¼K,
LK1 ¼ fllastg, IK1 ¼ fklastg and TK,llast is the analogue of SK,klast .
With
T0,l ¼ 0, l ¼ 1, . . . ,K
we can write for each j  1
Tj,l ¼ Tj1,l þmjl þ 	j,l
ffiffiffiffiffiffiffiffiffiffi
mj2
q
þ j
ffiffiffiffiffiffiffiffiffiffi
mj2
q
ð8Þ
where the 	j,l and j are independent N(0, 1) random variables.
After the data-gathering part of stage j, the treatment l j with the lowest Tj,l for l 2 Lj1 is
eliminated, leaving
Lj ¼ Lj1nfl j g
After the penultimate stage K  1, only one treatment, llast say, remains. This is observed in stage K
and if
TK,llast4 c
H0 : llast  0 is rejected in favour of llast4 0.
We shall establish the desired FWER property by a coupling argument, which assumes the terms
j in equations (7) and (8) are equal and which reuses values 	j,l in equation (8) as values for some of
the j,k in equation (7). It is straightforward to see that the model for Trial 1 given by equation (7)
and the model for Trial 2 given by equation (8) follow the correct distributional assumptions. The
type-I error rate for Trial 1 is , by construction. Thus, if we can demonstrate that a type-I error is
made in Trial 1 whenever a type-I error is made in Trial 2, it follows that Trial 2 has the smaller
type-I error probability – and so this must be no greater than .
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A key step in the coupling argument is to define the relationship between treatments k 2 Ij1
and l 2 Lj1, which specifies how values 	j,l in equation (8) are to be used as values for the j,k in
equation (7). Define
N0 ¼ fl : l  0g
and, as noted previously,
Nj ¼ l : l 2 Lj and l  0
	 

, for j ¼ 1, . . . ,K 1
For j¼ 0, define

0 lð Þ ¼ l, for each l 2 N0
In applying equation (8) for j¼ 1, generate independent random variables 1  Nð0, 1Þ and
	1,l  Nð0, 1Þ, l 2 L0. Then, in applying equation (7) for j¼ 1, use the same value 1 as in
equation (8), set
1,
0ðl Þ ¼ 	1,l for each l 2 N0
and generate the remaining 1,k values as additional independent N(0, 1) variates. It follows that
T1,l  S1,
0ðl Þ for each l 2 N0 ð9Þ
Our aim is to define injective functions 
j from Nj to Ij at the end of each stage j ¼ 1, . . . ,K 1,
such that
Tj,l  Sj,
j ðl Þ for each l 2 Nj ð10Þ
Intuitively, this means that for each treatment arm in Trial 2 that has a treatment effect less than or
equal to zero, and so would produce a type-I error if the associated null hypothesis were rejected,
there is a treatment arm in Trial 1 which has a treatment effect of zero and more positive current
data – and so this should be more inclined to lead to a type-I error. Finally, after stage K, we have
the control and just one treatment, klast in Trial 1 and llast in Trial 2 and final statistics SK,klast
and TK,llast .
Assuming we can define the desired functions 
j, there are two possibilities at the end of the trial
when stage j¼K is completed. The first possibility is that, on entering stage K, the set NK1 is empty
and a type-I error cannot be made in Trial 2. The second is that NK1 is nonempty and contains a
single element, so llast  0 and 
K1ðllastÞ ¼ klast (the only element of IK1): before the final-stage
data are seen
TK1,llast  SK1,klast
then with the (coupled) final-stage data
TK,llast  SK,klast
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A type-I error in Trial 2 requires TK,llast4 c and this can only occur if
SK,klast4 c
in which case a type-I error is also made in Trial 1. This establishes the desired property that a
type-I error is made in Trial 1 whenever a type-I error is made in Trial 2 and the FWER
result follows.
It remains to show that injective functions 
j from Nj to Ij, j ¼ 1, . . . ,K 1, can be defined with
the required property as expressed in equation (10). For the case j¼ 1, we know that equation (9)
holds before a treatment is eliminated at the end of stage 1 and we need to define a function 
1 from
N1 to I1 satisfying equation (10) with j¼ 1, after the first treatment has been eliminated. The
eliminated treatments are k1 in Trial 1 and l

1 in Trial 2, where
S1,k
1
 S1,k for k 2 I0, k 6¼ k1 ð11Þ
and
T1,l
1
 T1,l for l 2 L0, l 6¼ l1
In defining 
1 from N1 to I1, we need to consider values l 2 N1 ¼ N0nfl1g. For each value l 2 N1 with

0ðl Þ 6¼ k1, we set

1ðl Þ ¼ 
0ðl Þ 2 I1 ¼ I0nfk1g
It follows from equation (9) that T1,l  S1,
1ðl Þ for these values of l. Now suppose there is a value
~l 2 N1 for which 
0ð ~l Þ ¼ k1 and thus 
0ð ~l Þ =2 I1 ¼ I0nfk1g. In this case, we can set 
1ð ~l Þ to be any
index in I1, which is not already defined as 
1ðl Þ for some other l 2 N1 (since I1 has at least as many
elements as N1, there will be at least one option to choose here). The resulting 
1 has the injective
property. Now, by equations (9) and (11)
T1, ~l  S1,
0ð ~l Þ ¼ S1,k1  S1,
1ð ~l Þ
so equation (10) is satisfied for j¼ 1 and l ¼ ~l. This completes the definition of 
1.
The construction of functions 
j for j ¼ 2, . . . ,K 1 and proof of their properties continues by
induction. For a general j, we apply equations (7) and (8) using the same j in both cases and with
j,
j1ðl Þ ¼ 	j,l for each l 2 Nj1
With property (10) for j  1, we have
Tj1,l  Sj1,
j1ðl Þ for each l 2 Nj1
and because of the common values of j,
j1ðl Þ and 	j,l and the common j arising in equations (7) and
(8), this ensures that
Tj,l  Sj,
j1ðl Þ for each l 2 Nj1
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Thus, we can define 
j by setting

j ðl Þ ¼ 
j1ðl Þ 2 Ij
for each value l 2 Nj with 
j1ðl Þ 6¼ kj . If there is a value ~l 2 Nj for which 
j1ð ~l Þ ¼ kj , we can set

j ð ~l Þ to be any element of Ij which is not already defined as 
j ðl Þ for some other l 2 Nj. The same
reasoning as in the case j¼ 1 shows that the resulting 
j from Nj to Ij has the injective property and
satisfies equation (10), which proves the inductive step.
As noted earlier, if last  0, the inductive properties at stage K imply that before collecting the
final-stage data, we have 
K1ðllastÞ ¼ klast and
TK1,llast  SK1,klast
then with the (coupled) final-stage data,
TK,llast  SK,klast
A type-I error in Trial 2 requires TK,llast4 c and this can only occur if
SK,klast4 c
in which case a type-I error is also made in Trial 1, as required.
5 Results
5.1 Motivating trial
As a case study for the results in this paper, we consider the currently ongoing TAILoR trial, the
design of which is discussed in Magirr et al.2 This trial was originally designed to test four
different doses of Telmisartan. Telmisartan is thought to reduce insulin resistance in HIV-
positive individuals on combination antiretroviral therapy. The primary end point was
reduction in insulin resistance in the telmisartan-treated groups in comparison with the control
group as measured by homeostatic model assessment – insulin resistance (HOMA-IR) at 24 weeks.
A group-sequential MAMS design was used to avoid assumptions regarding monotonicity of
dose–response relationship, which were thought to be invalid based on a previous trial of the
treatment in a different indication.
The trial design controls the FWER at 0.05 with 90% power under the LFC with
ð1Þ ¼ 0:545, ð0Þ ¼ 0:178, 2 ¼ 1. The value of (1) was chosen so that the probability of a patient
allocated to a treatment with treatment effect (1) having a better treatment response than a patient,
given the control treatment was 0.65. The value of (0) was chosen to make the corresponding
probability 0.55.
5.2 Comparison of two- and three-stage drop-the-losers designs
We first show that extending the drop-the-losers design beyond two stages can be worthwhile. For
ð, 1 , ð1Þ, ð0ÞÞ ¼ ð0:05, 0:9, 0:545, 0:178Þ, and selected values of K, we used equations (5) and (6)
to find the required sample size of the one-stage design (with no interim analysis), a two-stage drop-
the-losers design and a three-stage drop-the-losers design. For each multi-stage design, a value n is
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specified and n patients are assigned to each remaining treatment and the control in each stage. For
each three-stage design, the number of treatments proceeding to stage 2 was chosen to give the
lowest total sample size.
Table 1 shows the required total sample size for each type of design when there are K¼ 3, 4, 6
and 8 experimental treatments (recall that the full sample size is always used, so there is no
dependence of sample size on the actual treatment effects). The table also shows the percentage
reduction in sample size when the number of stages is increased from 1 to 2 and from 2 to 3. The
benefits gained by including a third-stage increase with the number of treatments. It is likely that
at least K¼ 4 experimental treatments are necessary before the additional administrative burden of
a third stage would be deemed worthwhile. For K as large as 6 or 8, the reduction in sample size
in going from 1 to 2 stages is similar to that gained in moving from 2 to 3 stages, so if a first
interim analysis is regarded as cost effective, then a second interim analysis should also be
worthwhile.
5.3 Comparison of three-stage group-sequential MAMS and
drop-the-losers designs
We now compare sample size properties of drop-the-losers designs with those of group-sequential
MAMS designs when design parameters are specified as in the previous section. The group-
sequential MAMS designs have three analyses and use the triangular test boundaries of
Whitehead and Stratton,7 which are known to give good expected sample size properties.4
Figure 1 shows boxplots of the sample size distribution (using 250,000 replicates) for the three-
stage group-sequential MAMS designs with K¼ 4 and K¼ 6 experimental arms under four
scenarios: (1) under HG; (2) under the LFC; (3) when 1¼ 2¼. . .¼ K¼ (0) and (4) when
1¼ 2¼. . .¼ K¼(0). The solid black line in each boxplot represents the median sample size.
The dashed line for each K represents the fixed sample size of the most efficient three-stage drop-the-
losers designs (4 : 2 : 1 for K¼ 4 and 6 : 3 : 1 for K¼ 6).
Although the group-sequential MAMS designs with triangular test boundaries are known to have
low expected sample sizes, Figure 1 shows that the sample size distribution is highly variable and
depends strongly on the configuration of treatment effects. If we take the median sample size of the
group-sequential MAMS design as a point of comparison, we see the sample size for the drop-the-
losers design is higher under HG (Scenario 1), almost equal under the LFC (Scenario 2) and lower
Table 1. Sample sizes required for a one-stage design and two-stage and three-stage drop-the-losers
designs with ¼ 0.05, ¼ 0.1, (1)¼ 0.545 and (0)¼ 0.178.
Total sample size required for 90% power Percentage reduction in sample size
K J¼ 1 J¼ 2 J¼ 3 J¼ 1 to J¼ 2 J¼ 2 to J¼ 3
3 312 282 270 9.6 4.2
4 420 364 330 13.3 9.3
6 637 531 455 16.6 14.3
8 864 715 585 17.2 18.2
Note: For each three-stage design, the number of treatments proceeding to stage 2 is chosen to give the lowest total
sample size: in the notation of Section 2, these designs are 3:2:1 for K¼ 3, 4:2:1 for K¼ 4, 6:3:1 for K¼ 6 and 8:3:1
for K¼ 8.
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when all treatment effects are equal to (0) (Scenario 3). These results are generally encouraging for
the drop-the-losers design and show that the constraint of a fixed total sample size can be met
without sacrificing much efficiency in terms of average numbers of patients recruited.
The performance of the drop-the-losers design is poorest in Scenario 4 where all the treatment
effects are negative and the MAMS designs are likely to stop the whole trial early for futility. Results
for this scenario indicate the desirability of adding a futility rule to the drop-the-losers design:
although some variation in total sample size would be introduced, ethical considerations argue
against continued use of treatments which are proving ineffective. One might, for example,
specify a minimum requirement for treatments to meet at each stage and allow fewer than the
specified number to continue when some treatments fail to meet this requirement – or stop the
trial completely if no treatment satisfies the requirement. If a rule of this type was superimposed on
the drop-the-losers design with no other changes to sample numbers or the final critical value, c, the
type-I error rate would simply be reduced. Alternatively, the calculations of Section 3.1 could be
extended to include this form of futility rule and the design parameters adjusted to satisfy the type-I
error rate requirement exactly.
6 Spacing of interim analyses when there is delay between recruitment and
assessment of patients
In previous sections, we have assumed there is no delay between recruitment and assessment
of patients. In reality, there will nearly always be some delay, and often it will be
considerable. For example, in the TAILoR trial, the final end point is measured 24 weeks
after treatment.
Figure 1. Sample size distribution for three-stage group-sequential MAMS designs with K¼ 4 and K¼ 6 and four
vectors of treatment effects. Scenario 1 – the global null hypothesis (HG); scenario 2 – the LFC; Scenario 3 – all
experimental treatments have uninteresting treatment effect (0); Scenario 4 – all experimental treatments have effect
 0ð Þ. The dashed red line gives the required sample size for the three-stage drop-the-losers design with the same
parameters used: ¼ 0.05, ¼ 0.1, (1)¼ 0.545, (0)¼ 0.178.
520 Statistical Methods in Medical Research 26(1)
A delay between recruitment and assessment means that at the time of an interim analysis, there
will be patients who have been recruited but not yet assessed, and thus contribute no information to
that interim analysis. The efficiency of the trial, in terms of number of patients recruited, is then
reduced as some patients will be recruited to arms that are dropped before their responses are
measured. Also, with a delay in response there are fewer observations at each interim analysis
and, thus, lower probabilities of selecting the best treatments. The potential loss of efficiency
depends on the recruitment rate to the trial since this rate and the time at which the final end
point is measured together determine the numbers of patients treated but not assessed at the
interim analyses.
Hampson and Jennison15 have proposed ways of using partial information from patients who
have been recruited but not assessed at the time of an interim analysis. If a short-term end point that
is correlated with the final end point is available, fitting a joint model for both end points can
increase the information for the final end point. When the final end point is the incidence of an
event before a certain time, t* say, inference can be based on a Kaplan–Meier estimate of the
probability of the event occurring before t*. In this case, the time-to-event data for all patients is
used, with right censoring applying when the follow-up time is less than t* and the event has not yet
occurred.
When there is a delay in response, the methodology described in Sections 3.1–3.3 can still be
applied by conducting analyses at times when the required numbers of observations become
available. We have explored the optimal spacing of analyses when there is a known delay. Since
we have efficient computational methods for drop-the-losers designs, it is quite feasible to explore a
wide variety of spacings. We report results for an example in which the primary end point is
measured 24 weeks after recruitment, as in the TAILoR trial, and we consider recruitment rates
of m¼ 1, 2 and 4 patients per week. The limiting case m¼ 0 is also included to represent the case of
an immediate response.
We consider the 4:2:1 and 4:1 designs with, as before, (1)¼ 0.545, (0)¼ 0.178, ¼ 0.05 and
1  ¼ 0:9. We have explored a grid of possible spacings for each design. For the 4:2:1 design,
spacings are expressed in terms of parameters (1, !2, !3) defined as follows: if the initial group size of
a design is n and the spacing is (1, !2, !3), the first interim analysis takes place after n patients have
been recruited to each treatment arm, the second after a further !2n patients have been recruited to
each remaining arm and the last analysis occurs after recruiting and assessing a further !3n patients
on the remaining treatment and control arms. Thus, the total numbers recruited by analyses 1 and 2
are 5n and 5nþ 3!2n, respectively, but the numbers of observations seen at these analyses are lower
since not all of these patients have been assessed. At the final analysis, all 5nþ 3!2nþ 2!2n patients
have been assessed. We assume that once the decision has been made to drop an experimental arm,
that decision cannot be reversed after seeing data from patients who were previously recruited but
not assessed. For the 4:1 design, spacings are expressed in terms of parameters (1, !2), where the first
interim analysis takes place after n patients have been recruited to each treatment arm and an
additional !2n are recruited to the selected treatment and control in the second stage.
For each type of design, we searched over possible choices of !2 and !3 to find the design with the
lowest total sample size. Table 2 shows the optimal values of !2 and !3 and the total sample size for
two-stage and three-stage designs under specified values of m, the number of patients recruited per
week. For comparison, the design that tests four experimental treatments without any interim
analyses requires 420 patients in total. Table 2 shows the optimal spacing parameters and total
sample size for both designs when the mean number of patients recruited per week, m, varies. Note
that the design that tests four experimental treatments without any interim analyses requires 420
patients in total.
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Table 2 shows that as the recruitment rate increases, there is a lower efficiency gain from including
interim analyses. With a single interim analysis, the reduction in sample size of 14% in the case of
immediate response falls to 7.1% when m¼ 2 and is lost completely for m¼ 4. The advantage of a
three-stage design over a two-stage design also falls as m increases. Optimising the timing of the
interim analyses is important here. As an example, with m¼ 2, a 4:2:1 design with equally spaced
interim analyses, that is, (!2, !3)¼ (1, 1), needs a total of 390 patients, compared to the 363 patients
for a design with the optimal spacing.
In view of these results, it is advisable to assess the likely impact of a delay in response on the
efficiency of an adaptive design. Nevertheless, we have still seen that, for plausible combinations of
recruitment rate and time to response, including either one or two interim analyses can reduce the
sample size requirement compared to a design without interim analyses.
7 Discussion
MAMS designs are of great interest in practice, as their use means more new treatments can be
tested with the same limited pool of patients. Much of the methodology about designing MAMS
trials has focused on designs in which treatments are dropped early if their test statistics are below
some prespecified futility boundary. This leads to variability in the number of treatments that will be
in the trial at each stage, and therefore uncertainty in the total sample size required. This leads to
uncertainties in applying for funding to conduct a MAMS trial, as well as other logistical issues such
as staff employment. A design that does have a fixed sample size is the two-stage drop-the-losers
design, where multiple experimental treatments are evaluated at an interim analysis, then the best-
performing experimental treatment goes through to the second stage. We have investigated design
issues in extending the drop-the-losers design to have more than two stages. If there are four or more
treatments, we find that a third stage results in a considerable reduction in sample size. In addition,
the fixed sample size compares well to the median sample size used in a group-sequential MAMS
design. The design therefore retains many of the efficiency benefits of a MAMS design whilst also
having a fixed sample size, which is very useful in practice. We have mainly considered the utility of
adding a third stage, as each additional interim analysis increases the administrative burden of the
trial. Adding a fourth stage provides a substantially lower additional efficiency advantage unless
there are a lot of treatments being tested.
In this paper, we assumed a known variance of the normally distributed outcome. However, the
method of quantile substitution, described in Section 3.8 of Jennison and Turnbull,16 can be used to
change the final critical value so that the type-I error rate is controlled when the variance is estimated
Table 2. Properties of 4:2:1 and 4:1 designs when there is a 24-week delay between recruitment and
assessment.
Optimal spacing Max SS Percentage reduction in SS
m J¼ 2 J¼ 3 J¼ 2 J¼ 3 J¼ 2 J¼ 3
0 (1, 0.9) (1, 0.9, 0.8) 361 326 14.0 9.7
1 (1, 0.8) (1, 0.9, 0.45) 377 344 10.2 8.8
2 (1, 0.5) (1, 0.95, 0.2) 390 363 7.1 6.9
4 (1, 0.35) (1, 0.75, 0.05) 422 405 0.5 3.6
Note: A constant recruitment rate of m patients per week is assumed. Here, SS denotes sample size and m¼ 0
represents the limiting case when there is no delay in observing the response.
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from the data. We carried out simulations that showed this method performs very well in practice
(results not shown), similarly to the group-sequential17 and group-sequential MAMS cases.4
In practice, the requirement to drop a fixed number of treatments at each stage may be difficult to
keep to. For example, if all treatments are performing poorly in comparison to control, then it may
be unethical to continue with even the best performing treatment. Any changes to the design during
the trial will affect the operating characteristics of the trial. However, dropping more treatments
than planned will lead to a lower than nominal FWER rather than an inflation. If one wishes to keep
more treatments in the trial than originally planned, then this will lead to an inflation in FWER.
However, by modifying the final critical value suitably, this inflation can be reduced. The analytical
formulae in this paper can be modified in order to calculate the required critical value if more
sophisticated stopping rules are used.
An alternative design that controls the number of treatments passing each analysis but also allows
early stopping of the trial for futility or efficacy is the design of Stallard and Friede.9 The multi-stage
drop-the-losers design is somewhat less flexible than the Stallard and Friede design, but does have
the advantage of having analytical formulae that provide exact operating characteristics of the
design. The formulae for the Stallard and Friede design are conservative, especially when there
are more than two stages. Of course simulation could be used to evaluate the operating
characteristics exactly, but this makes it difficult to evaluate a large number of potential designs.
We have shown that this is important in the case of delay between recruitment and assessment,
where the spacing of the interim analyses becomes very important. The multi-stage drop-the-losers
design can be evaluated extremely quickly, which allows the optimal interim analysis spacing to be
found.
One worrying factor for the efficiency of adaptive trials in general, and the drop-the-losers design
specifically, is delay between recruiting a patient and assessing their outcome. Such delay means that
at a given interim analysis, there will be patients who are recruited but not yet assessed. These
patients will not contribute to that interim analysis or to any subsequent analysis if the treatment
they are on is dropped. We have investigated the effect of delay and show that drop-the-losers
designs can still provide efficiency gains over a multi-arm design without interim analyses if the
recruitment rate is below some level. This level will depend on the extent of delay and the total
sample size of the trial. There are two factors that may go someway towards mitigating the impact of
delay. Firstly, there may well be early outcomes that correlate well with the final outcome.18 For
example, in the TAILoR trial, the final outcome is HOMA-IR at 24 weeks, but if earlier
measurements could be made, these may well be highly informative for the 24 week end point. In
that case, more patients could be included in the interim analysis. A second factor is that trial
recruitment tends to start slowly and increase over time, perhaps as more centres are added to
the trial. This means that a greater proportion of patients may be available for assessment at
earlier interim analyses compared to the uniform recruitment case we considered here. Research
into the effect of delay on group-sequential MAMS trials and strategies to account for it (extending
the work of Hampson and Jennison15 to multi-arm trials) would be very useful.
This paper has considered design issues in multi-stage drop-the-losers trials. A drawback of
adaptive designs in general is that estimation of relevant quantities, such as the mean treatment
effect, after the trial is more complicated than in a traditional trial. For example, using the maximum
likelihood estimate in two-stage trials will result in bias.19,20,21 The issue of estimation for multi-stage
drop-the-losers trials is considered in Bowden and Glimm.22
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